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Michael J. Thorpy, MB, ChB,1 Colin Shapiro, MBBCh, PhD,2 Geert Mayer, MD,3
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Dan Chen, MD, PhD,8 Lawrence P. Carter, PhD,8,9 Hao Wang, PhD,10 Yuan Lu, MS,9
Jed Black, MD,8,11 and Yves Dauvilliers, MD, PhD12
Objective: Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with wake-promoting
effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy.
Methods: Patients with narcolepsy with mean sleep latency <25 minutes on the Maintenance of Wakefulness Test
(MWT), Epworth Sleepiness Scale (ESS) score ≥ 10, and usual nightly sleep ≥6 hours were randomized to solriamfetol
75, 150, or 300 mg, or placebo for 12 weeks. Coprimary endpoints were change from baseline to week 12 in MWT
and ESS. Improvement on the Patient Global Impression of Change (PGI-C) was the key secondary endpoint.
Results: Safety and modified intention-to-treat populations included 236 and 231 patients, respectively. Solriamfetol
300 and 150 mg were positive on both coprimary endpoints. Least squares mean (standard error [SE]) changes from base-
line were 12.3 (SE = 1.4) and 9.8 (SE = 1.3) minutes for solriamfetol 300 and 150 mg on the MWT, respectively, versus 2.1
(SE = 1.3) minutes for placebo, and −6.4 (SE = 0.7) for 300 mg and −5.4 (SE = 0.7) for 150 mg on the ESS versus −1.6
(SE = 0.7) for placebo (all p < 0.0001). At week 12, higher percentages of patients treated with solriamfetol 150 mg
(78.2%) and 300 mg (84.7%) reported PGI-C improvement relative to placebo (39.7%; both p < 0.0001). Adverse events
≥5% across all solriamfetol doses included headache (21.5%), nausea (10.7%), decreased appetite (10.7%), nasopharyngitis
(9.0%), dry mouth (7.3%), and anxiety (5.1%).
Interpretation: Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired
wakefulness and excessive sleepiness in patients with narcolepsy.
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Narcolepsy is a chronic neurological disorder resultingfrom the dysregulation of neurophysiologic pathways
that control the stability of sleep and wake states.1 Excessive
sleepiness (ES) and impaired daytime wakefulness are essen-
tial and somewhat independent symptoms of narcolepsy.2,3
These symptoms contribute to reductions in function, pro-
ductivity, and quality of life, and an increased risk for motor
vehicle accidents.4–9 Although ES and impaired wakefulness
are present in all individuals with narcolepsy,10 2 types of nar-
colepsy are recognized: type 1 and type 2, formerly known as
narcolepsy with and without cataplexy, respectively. Narco-
lepsy type 1 is characterized by the presence of cataplexy
and/or hypocretin deficiency as measured by reduced hypocre-
tin levels in the cerebrospinal fluid, and type 2 is characterized
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by the absence of cataplexy but the presence of relevant find-
ings on the Multiple Sleep Latency Test (ie, ≥2 sleep onset
rapid eye movement periods and sleep latency ≤8 minutes)
that are indicative of narcolepsy.10
Treatment of narcolepsy is symptomatically driven,
and management of ES generally relies on pharmacologic
intervention from several medication classes including the
central nervous system depressant sodium oxybate, stimu-
lants such as methylphenidate and amphetamines, and the
wake-promoting agents modafinil and armodafinil.2,11
Additionally, the wake-promoting agent pitolisant has
been recently approved for the treatment of narcolepsy in
Europe.12 However, current pharmacologic options may
be associated with factors such as poor tolerability, toler-
ance over time, abuse potential, and suboptimal response
that may preclude or limit their use in some patients.2,11
Solriamfetol (formerly known as JZP-110 and ADX-
N05) is a selective dopamine and norepinephrine reuptake
inhibitor that binds to dopamine and norepinephrine trans-
porters in vitro at concentrations in the micromolar range,
inhibiting reuptake without promoting the release of mono-
amines.13 Solriamfetol is distinguished from other wake-
promoting agents by its dual reuptake inhibition at
dopamine and norepinephrine transporters, and is distin-
guished from the amphetamine stimulants by its lack of
release of monoamines.14,15 Together, these differences may
account for the robust wake-promoting effects and the lack
of rebound hypersomnia that have been observed in rodent
models of narcolepsy.13,16 In 2 phase 2 controlled clinical
trials in adult patients with narcolepsy, solriamfetol reduced
patient-reported ES as measured on the Epworth Sleepiness
Scale (ESS) and improved wakefulness as measured by the
objective Maintenance of Wakefulness Test (MWT).17,18
This phase 3 trial was initiated to demonstrate the effi-
cacy and safety of solriamfetol for the treatment of ES and
impaired wakefulness in patients with narcolepsy type 1 or
type 2.
Patients and Methods
Study Design and Study Participants
This was a clinical trial from the Treatment of Obstructive
Sleep Apnea and Narcolepsy Excessive Sleepiness (TONES)
phase 3 program, the TONES 2 study. This phase 3,
double-blind, randomized, placebo-controlled, parallel-
group study (ClinicalTrials.gov identifier NCT02348593,
EudraCT number 2014-005487-15) was performed at
50 study centers in the United States and Canada, and 9 cen-
ters in Finland, France, Germany, and Italy. The study was
approved by the institutional review board or independent
ethics committee for each study center, and was performed
in accordance with the Declaration of Helsinki; all patients
provided written informed consent.
Eligible patients were 18 to 75 years old, with a diag-
nosis of narcolepsy type 1 or type 2 according to criteria in
either the International Classification of Sleep Disorders,
3rd edition (ICSD-3)10 or Diagnostic and Statistical Man-
ual of Mental Disorders, 5th edition (DSM-5).19 The
DSM-5 criteria include patients who have been diagnosed
with narcolepsy based on the presence of cataplexy and
were applied in this study to include such patients who
had been diagnosed with narcolepsy on the basis of cata-
plexy under ICSD-2 but who no longer meet diagnostic
criteria based on a history of cataplexy under ICSD-3.
Additional inclusion criteria were baseline mean sleep
latency <25 minutes on the first 4 trials of a 5-trial,
40-minute MWT,20 baseline ESS21 score ≥ 10, usual
nightly total sleep time ≥ 6 hours (by self-report), and a
body mass index between 18 and 45 kg/m2. The presence
of any clinically relevant untreated medical, psychiatric, or
behavioral disorder or medical condition other than narco-
lepsy that is associated with ES (ie, night-time or variable
shift work) was reason for exclusion, as was a history or
presence of any acutely unstable medical or psychiatric
disorder, or surgical history that could affect the safety of
the patient; female patients who were pregnant or lactating
were also excluded. Although use of medications that could
affect the evaluation of ES or cataplexy was also reason for
exclusion, patients could be enrolled if prior use had
stopped for >5 half-lives of the drug and the patient had
returned to baseline level of daytime sleepiness ≥7 days
prior to the baseline visit.
Randomization and Masking
Stratified randomization was performed based on the
presence or absence of cataplexy, with patients assigned in a
1:1:1:1 ratio to treatment with solriamfetol 75, 150, or
300 mg, or placebo. The investigator accessed an Interactive
Voice Response System or an Interactive Web Response
System to randomize eligible patients.
All study personnel were blinded to the study treat-
ments, and a double-blind approach was used whereby all
study drugs were prepared in identical opaque gelatin cap-
sules to ensure adequate blinding.
Interventions and Outcomes
Patients who met all inclusion and no exclusion criteria
and were randomized to the treatment groups received
oral placebo or solriamfetol 75, 150, or 300 mg once daily
for 12 weeks. Patients who were randomized to the
150 and 300 mg doses received 75 and 150 mg, respec-
tively, on days 1 through 3 of the first week, with the full
dose commencing on day 4.
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The coprimary endpoints were change from baseline
to week 12 on (1) MWT mean sleep latency on the first
4 trials of the MWT and (2) ESS score. The MWT was
performed after in-clinic overnight polysomnography at
baseline and weeks 1, 4, and 12 or early termination, and
the ESS was completed by the patients at baseline and
weeks 1, 4, 8, and 12 or early termination. If data from
≥2 of the first 4 individual MWT trials were missing at a
given time point, the mean sleep latency on the MWT
was set to missing at that specific time point. If data from
only 1 of the first 4 individual MWT trials were missing,
the mean of the remaining 3 of the first 4 MWT trials
was used for calculating the mean sleep latency on the
MWT for that individual at that specific time point. The
ESS total score is the sum of 8 item scores. If ≥3 item
scores on the ESS were missing at a specific time point,
the ESS total score was set to missing. If only 1 or 2 ESS
items were missing at a specific time point, the mean of
the remaining 7 or 6 nonmissing ESS items for that indi-
vidual at that time point was used to impute the missing
ESS items. In these cases, the ESS total score was calcu-
lated as the sum of the observed and the imputed item
scores.
The percentage of patients who reported improvement
on the Patient Global Impression of Change (PGI-C)22 at
week 12 was the key secondary endpoint. Other secondary
endpoints were time course on the MWT as measured by
the change in sleep latency on each of the 5 MWT trials;
change in the mean sleep latency from baseline to week 4;
change in ESS from baseline to weeks 1, 4, and 8; per-
centage of patients who reported improvement on the
PGI-C at weeks 1, 4, and 8; and percentage of patients
reported improved at weeks 1, 4, 8, and 12 on the Clini-
cal Global Impression of Change (CGI-C).22 Improve-
ments on the global scales were defined by responses
reflecting “minimal,” “much,” or “very much” improved.
Change in the mean and median weekly number of cata-
plexy attacks was an exploratory endpoint among the sub-
group of patients who reported the presence of cataplexy.
These patients completed a cataplexy frequency diary to
record the number of cataplexy attacks that they had each
day, beginning after discontinuation of narcolepsy medica-
tion and through week 12.
Safety and tolerability evaluation included the inci-
dence of all adverse events reported by the patients, who
were queried about adverse events at each clinic visit and
during telephone contact calls for the weeks where no
clinic visits were scheduled, as well as those adverse events
noted by the investigator. Weight, vital signs, electrocar-
diograms, and the Columbia-Suicide Severity Rating
Scale23 were assessed at each clinic visit. On the days
when MWT was performed, blood pressure and heart rate
measurements were collected at 7 time points, with the
average of these time points from predose to 9 hours post-
dose used for evaluating change from baseline. Addition-
ally, blood pressure and heart rate were assessed at
30-minute intervals using 24-hour ambulatory blood pres-
sure monitoring at baseline and at week 8. Mean values
for blood pressure and heart rate were calculated over the
24-hour period for each individual, and mean changes
from screening to week 8 were summarized.
Statistical Analyses
Accounting for withdrawals, approximately 240 patients
were planned for enrollment, approximately 60 for each
treatment group. This sample size was based on an estimate
of 54 patients per group to provide at least 80% power to
detect a difference of 6 minutes in the mean sleep latency
time as determined from the MWT (mean of the first 4 tri-
als) and a difference of 4 points on the ESS changes from
baseline to week 12 between each solriamfetol treatment
dose group and placebo. These estimates were based on the
effects observed at the 150 and 300 mg doses in 2 phase
2 studies.17,18 This calculation also assumed standard devi-
ations (SDs) in the changes from baseline of 10 minutes
for the MWT and 6 points for the ESS, and a 2-sided sig-
nificance level of 0.05 using a t test.
Efficacy analyses were based on the modified
intention-to-treat (mITT) population, defined as all ran-
domized patients who received at least 1 dose of study
drug, and had baseline and at least 1 postbaseline evalua-
tion by MWT or ESS. Both MWT and ESS endpoints
were analyzed using a mixed-effect repeated measures
model, including fixed effects for treatment (ie, dose
group), visit (as a discrete and repeated factor), treatment-
by-visit interaction, baseline value of the corresponding
endpoint (as a continuous covariate), and randomization
stratification factor (ie, presence or absence of cataplexy).
The response variable was the change from baseline to each
postbaseline visit, and the coprimary endpoints were the
changes from baseline to week 12. The least squares
(LS) mean and the standard error (SE) of treatment differ-
ence versus placebo and their 95% confidence intervals
(CIs) were presented. The PGI-C and CGI-C were ana-
lyzed using chi-squared tests. A fixed hierarchical testing
procedure was used to correct for multiplicity, starting with
the highest solriamfetol dose for the coprimary endpoints
and followed by the key secondary endpoint. Both coprim-
ary endpoints (MWT and ESS) had to be significant at the
0.05 level in the primary analysis for testing to proceed to
the key secondary endpoint (PGI-C); testing proceeded
in the order specified above for each subsequent lower
dose with statistical significance claimed only for those
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outcomes above the break in the hierarchy. Nominal
p values are presented for differences below the hierarchical
break.
In addition to the primary analyses described above,
4 sensitivity analyses were performed to assess the impact
of missing data on the coprimary endpoints. For the
MWT and ESS, 2 single imputation approaches (last
observation carried forward and mean imputation) and
2 multiple imputation approaches (Markov chain Monte
Carlo with regression method24 and Pattern Mixture
model using dropout pattern imputation method25) were
conducted. In addition, for the key secondary endpoint of
PGI-C, 2 single imputation approaches (worst case and
varies by early termination reason) were conducted to
assess the impact of missing data. All analyses were per-
formed using SAS v9.3 or later (SAS Institute, Cary, NC).
Results
Patient Population
Of the 239 patients who were randomized, 236 received
at least 1 dose of study drug and were included in the
safety population (Fig 1). The mITT population consisted
of 231 patients; 1 patient randomized to placebo and
4 patients randomized to solriamfetol 150 mg did not
have baseline or at least 1 postbaseline efficacy assessment
of MWT and ESS. The discontinuation rate was highest
in the solriamfetol 300 mg group (27.1%, with lack of
efficacy [10.2%, n = 6] and adverse events [8.5%, n = 5]
as the most common reasons for discontinuation), followed
by the solriamfetol 75 mg (16.9%), placebo (10.3%), and
solriamfetol 150 mg (7.3%) groups (see Fig 1). Discontinu-
ation due to lack of efficacy did not appear to be dose-
related. Three of the 6 patients who discontinued due to
lack of efficacy in the 300 mg group and 3 of the 4 patients
who discontinued due to lack of efficacy in the 75 mg
group had cataplexy at screening and had discontinued
their anticataplectic medication(s) prior to starting study
drug on day 1 of the current study.
Demographic and clinical characteristics were similar
across treatment groups (Table 1). Overall, the majority of
patients (64.4%) were rated by clinicians as moderately or
markedly ill and were characterized by impaired wakeful-
ness and ES, as indicated by baseline MWT mean sleep
latency of 7.5 (SD = 5.7) minutes and ESS scores of 17.2
(SD = 3.2), respectively. Most patients (90.7%) had prior
use of psychostimulants; prior use of sodium oxybate and
antidepressants was reported for 25.8% and 34.7% of
patients, respectively. Cataplexy was present in 50.8% of
patients overall, with similar percentages of patients with
FIGURE 1: Patient disposition.
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cataplexy in each of the treatment groups (see Table 1);
demographic and baseline characteristics were similar
between patients with cataplexy and those without cata-
plexy (data not shown).
Efficacy
Solriamfetol 300 mg and 150 mg doses met the coprim-
ary endpoints of MWT and ESS as well as the percentage
of patients who reported improvement on the PGI-C (all
p < 0.0001; Table 2). Significance was not achieved for
solriamfetol 75 mg on the MWT.
The LS mean change from baseline at week 12 on the
MWT showed an increase in mean sleep latency of 12.3
(SE = 1.4) and 9.8 (SE = 1.3) minutes with solriamfetol
300 mg and 150 mg, respectively, which was significant
compared with 2.1 (SE = 1.3) minutes for placebo (both
p < 0.0001; Fig 2A). These changes resulted in LS mean
differences versus placebo of 10.1 (95% CI = 6.4–13.9)
minutes for solriamfetol 300 mg and 7.7 (95% CI = 4.0–11.3)
TABLE 1. Baseline Demographic and Clinical Characteristics of the Safety Population
Characteristic Placebo, n = 59 Solriamfetol Total, N = 236
75 mg, n = 59 150 mg, n = 59 300 mg, n = 59
Age, yr 36.0  15.2 36.5  12.8 38.1  13.0 34.3  11.5 36.2  13.2
Sex, n
M 24 (40.7%) 22 (37.3%) 17 (28.8%) 19 (32.2%) 82 (34.7%)
F 35 (59.3%) 37 (62.7%) 42 (71.2%) 40 (67.8%) 154 (65.3%)
Race, n
Asian 0 0 3 (5.1%) 3 (5.1%) 6 (2.5%)
Black or African American 10 (16.9%) 12 (20.3%) 6 (10.2%) 5 (8.5%) 33 (14.0%)
White 47 (79.7%) 46 (78.0%) 48 (81.4%) 48 (81.4%) 189 (80.1%)
Other 2 (3.4%) 1 (1.7%) 2 (3.4%) 3 (5.1%) 8 (3.4%)
BMI, kg/m2 29.1  6.0 27.9  5.4 27.9  5.8 28.1  6.3 28.3  5.9
Presence of cataplexy, n 29 (49.2%) 31 (52.5%) 30 (50.8%) 30 (50.8%) 120 (50.8%)
MWT sleep latency, minutesa 6.1  5.6 7.5  5.4 7.7  5.6 8.7  6.2 7.5  5.7
ESS scoreb 17.3  2.8 17.3  3.5 16.9  3.7 17.2  2.8 17.2  3.2
Baseline CGI-S score, n
1 = Normal, not at all ill 0 0 0 0 0
2 = Borderline ill 0 0 0 0 0
3 = Mildly ill 1 (1.7%) 3 (5.1%) 3 (5.1%) 1 (1.7%) 8 (3.4%)
4 = Moderately ill 14 (23.7%) 14 (23.7%) 16 (27.1%) 17 (28.8%) 61 (25.8%)
5 = Markedly ill 26 (44.1%) 20 (33.9%) 24 (40.7%) 21 (35.6%) 91 (38.6%)
6 = Severely ill 13 (22.0%) 17 (28.8%) 13 (22.0%) 12 (20.3%) 55 (23.3%)
7 = Among the
most extremely ill
4 (6.8%) 5 (8.5%) 3 (5.1%) 8 (13.6%) 20 (8.5%)
Missing 1 (1.7%) 0 0 0 1 (0.4%)
Values are mean  standard deviation or n (%).
aMWT measures a patient’s ability to stay awake for a given period of time. Patients were included if their baseline mean sleep latency was
<25 minutes on the first 4 trials of a 5-trial, 40-minute MWT.
bESS scores range from 0 to 24, with scores of 16–24 indicating severe excessive sleepiness.
BMI = body mass index; CGI-S = Clinical Global Impression of Severity; ESS = Epworth Sleepiness Scale; F = female; M = male; MWT = Mainte-
nance of Wakefulness Test.
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TABLE 2. Hierarchical Testing of Coprimary and Key Secondary Efficacy Endpoints in the Modified Intention-to-
Treat Population
Endpoint Solriamfetol, Treatment Difference from Placebo, Least Squares Mean (95% CI)

























A fixed hierarchical testing procedure was used to correct for multiplicity, starting with the highest solriamfetol dose for the coprimary endpoints and
followed by the key secondary endpoint; testing proceeded in that order for each subsequent lower dose, with statistical significance claimed only for
those outcomes above the break in the hierarchy.
aPatient Global Impression of Change is a patient self-reported, 7-point assessment, ranging from “very much worse” to “very much improved.”
bNominal p value, because it is below the hierarchical break.
FIGURE 2: Change from baseline in coprimary endpoints. (A) Least squares (LS) mean change in Maintenance of Wakefulness
Test (MWT) sleep latency from baseline in minutes for all treatment groups. (B) LS mean change in Epworth Sleepiness Scale
(ESS) score for all treatment groups. All p values are nominal at weeks 1, 4, and 8. SE = standard error.
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minutes for solriamfetol 150 mg. Although the LS mean
increase in sleep latency of 4.7 (SE = 1.3) minutes at the
75 mg dose was approximately 2-fold higher than that of
placebo, significance was not met (p = 0.1595).
For the ESS score (see Fig 2B), the LS mean change
from baseline at week 12 was −6.4 (SE = 0.7), −5.4
(SE = 0.7), and −3.8 (SE = 0.7) for the 300 mg, 150 mg,
and 75 mg doses of solriamfetol, respectively, and − 1.6
(SE = 0.7) with placebo. These reductions resulted in sig-
nificant LS mean differences versus placebo of −4.7 (95%
CI = −6.6 to −2.9, p < 0.0001) for solriamfetol 300 mg,
−3.8 (95% CI = −5.6 to −2.0, p < 0.0001) for solriamfetol
150 mg, and −2.2 (95% CI = −4.0 to −0.3, p = 0.0211)
for solriamfetol 75 mg.
Improvements were observed at all solriamfetol doses
at week 1 on the MWT (see Fig 2A). The magnitude of
effect remained stable over the 12 weeks of the study, and
the 300 and 150 mg doses differed from placebo at weeks
1 and 4. Similar patterns were observed on the ESS (see
Fig 2B), with reductions in ESS score relative to placebo
observed as early as week 1 with the 300 and 150 mg
doses, and effects remained stable over the study duration.
Evaluation of mean sleep latency on each of the
5 individual MWT trials at week 12 showed efficacy
beginning at 1 hour after dosing through 9 hours after
dosing for solriamfetol 150 and 300 mg (Fig 3).
Solriamfetol increased the percentage of patients
who reported improvement in their overall condition on
the PGI-C (Fig 4A). At week 12, these increases were
dose-dependent and were significant for solriamfetol
300 mg (84.7%) and 150 mg (78.2%) doses versus pla-
cebo (39.7%; both p < 0.0001); the 75 mg dose was
nominally significant (67.8%) compared with placebo
(p = 0.0023, but the comparison was below the hierarchi-
cal break). Effects were observed at all doses by week
1 and remained stable over the course of the study.
Similar patterns and percentages were observed on
the CGI-C (see Fig 4B). All doses resulted in higher per-
centages of patients who improved as early as week 1, with
effects at 300 mg and 150 mg maintained over the study.
The results of each of the sensitivity analyses across each
of the endpoints (MWT, ESS, and PGI-C) yielded similar
results and conclusions as the primary analyses of those
endpoints (Supplementary Table).
There was no clear effect of solriamfetol on the
number of cataplexy attacks per week among patients with
cataplexy, although this study was not powered or
designed to rigorously evaluate the effects of solriamfetol
on cataplexy (data not shown). Preliminary analyses26 did
not suggest any clinically meaningful differences in effi-
cacy or safety between narcolepsy patients with and with-
out cataplexy (manuscript in preparation).
Safety
The incidence of any adverse event was higher with sol-
riamfetol (68.4%) than with placebo (45.8%; Table 3).
Discontinuations due to adverse events were greater in the
solriamfetol 150 (5.1%) and 300 mg (8.5%) groups than
with placebo (1.7%); other than cataplexy, which resulted
in discontinuation in 2 patients, none of the adverse
events leading to study discontinuation occurred in >1
patient. One patient in the solriamfetol 150 mg group
had 2 serious adverse events of noncardiac chest pain and
anxiety that were deemed by the investigator not to be
FIGURE 3: Change from baseline in sleep latency for each of the 5 individual Maintenance of Wakefulness Test (MWT) trials at
week 12 (modified intent-to-treat population). Individual MWT trials, each of 40-minute duration, were performed at 2-hour
intervals at the times shown in parentheses, starting 1 hour after dosing. SE = standard error.
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related to study medication; this patient continued the
study without recurrence of the events.
Adverse events with an incidence ≥5% in combined
solriamfetol dose groups included headache (21.5%), nau-
sea (10.7%), decreased appetite (10.7%), nasopharyngitis
(9.0%), dry mouth (7.3%), and anxiety (5.1%; see
Table 3). A post hoc analysis was conducted of the inci-
dence of headache-related events, including headache and
migraine, in patients who either had or who did not have
headache, such as headache, migraine, tension headache, or
cluster headache, in their medical history. This analysis
showed that patients who had a medical history of head-
ache had a higher rate of headache during the study relative
to those without a medical history of headache (14.3% vs
4.4% in the placebo group, and 31% vs 19.3% in the com-
bined solriamfetol group). However, there did not appear
to be a differential increase in the incidence of headache or
migraine in the solriamfetol group compared with the pla-
cebo group between the subgroups of patients with and
without a medical history of headache. Insomnia was
reported in 2.8% of patients with solriamfetol and none
with placebo; no patient discontinued the study due to
insomnia.
No drug-related effects were found on clinical labora-
tory assessments. The average of vital signs taken from pre-
dose to 9 hours postdose showed an increase from baseline
in systolic and diastolic blood pressure (1–2 mmHg) and
heart rate (2–4 beats per minute) for solriamfetol 150 and
300 mg dose relative to minimal changes (<1 mmHg or
beats per minute) for placebo (Table 4). These effects
on blood pressure and heart rate from baseline to week
8 using 24-hour ambulatory blood pressure monitoring
were similar to what was observed during the days on
which MWT was performed (see Table 4). No patient had
FIGURE 4: Percentage of patients with global improvements. (A) Percentage of patients who reported improvement on the
Patient Global Impression of Change (PGI-C). (B) Percentage of patients reported to be improved on the Clinical Global
Impression of Change (CGI-C). Improvements on the global scales were defined by responses reflecting “minimal,” “much,” or
“very much” improved.
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a treatment-emergent adverse event of hypertension, and
2 patients had a treatment-emergent adverse event of blood
pressure increase (1 in the 150 mg group and 1 in the
300 mg group). Study drug was not interrupted in either
case, and both patients completed the study.
Discussion
This phase 3 study demonstrated the robust effects of sol-
riamfetol for improving wakefulness on the MWT and
reducing ES on the ESS in a large population of patients
with narcolepsy. This study also supports the safety and tol-
erability profile of solriamfetol. Solriamfetol demonstrated
dose-dependent efficacy that was significantly superior to
placebo on both coprimary endpoints at the 150 and
300 mg doses. The 75 mg dose resulted in significantly
greater improvement than placebo on the ESS but not on
the MWT.
Importantly, improvements on both coprimary end-
points were observed at week 1, and these effects were
maintained at the 150 and 300 mg doses over the study
duration, indicating that there was no apparent tolerance
over the 12 weeks of the study. Onset of efficacy at week
1 is consistent with what was observed previously in indi-
viduals with narcolepsy.18 Furthermore, on the MWT, sig-
nificant effects were observed across all 5 of the individual
TABLE 3. TEAEs in the Safety Population
TEAE Placebo, n = 59 Solriamfetol
All Doses, n = 177 75 mg, n = 59 150 mg, n = 59 300 mg, n = 59
Any TEAE 27 (45.8%) 121 (68.4%) 34 (57.6%) 47 (79.7%) 40 (67.8%)
Serious TEAE 0 1 (0.6%) 0 1 (1.7%) 0
TEAE leading to study
drug discontinuation
1 (1.7%) 9 (5.1%) 1 (1.7%) 3 (5.1%) 5 (8.5%)
Most common TEAEsa
Headache 3 (5.1%) 38 (21.5%) 6 (10.2%) 14 (23.7%) 18 (30.5%)
Nausea 1 (1.7%) 19 (10.7%) 3 (5.1%) 6 (10.2%) 10 (16.9%)
Decreased appetite 1 (1.7%) 19 (10.7%) 5 (8.5%) 5 (8.5%) 9 (15.3%)
Nasopharyngitis 3 (5.1%) 16 (9.0%) 5 (8.5%) 8 (13.6%) 3 (5.1%)
Dry mouth 2 (3.4%) 13 (7.3%) 3 (5.1%) 4 (6.8%) 6 (10.2%)
Anxiety 1 (1.7%) 9 (5.1%) 1 (1.7%) 3 (5.1%) 5 (8.5%)
Diarrhea 1 (1.7%) 8 (4.5%) 2 (3.4%) 3 (5.1%) 3 (5.1%)
Dyspepsia 0 6 (3.4%) 1 (1.7%) 2 (3.4%) 3 (5.1%)
Dizziness 2 (3.4%) 6 (3.4%) 2 (3.4%) 1 (1.7%) 3 (5.1%)
Fatigue 0 5 (2.8%) 0 2 (3.4%) 3 (5.1%)
Weight decreased 0 5 (2.8%) 1 (1.7%) 1 (1.7%) 3 (5.1%)
Upper respiratory
tract infection
1 (1.7%) 5 (2.8%) 1 (1.7%) 4 (6.8%) 0
Insomnia 0 5 (2.8%) 2 (3.4%) 0 3 (5.1%)
Constipation 1 (1.7%) 4 (2.3%) 3 (5.1%) 1 (1.7%) 0
Influenza 3 (5.1%) 4 (2.3%) 2 (3.4%) 1 (1.7%) 1 (1.7%)
Heart rate increased 0 4 (2.3%) 0 0 4 (6.8%)
Weight increased 3 (5.1%) 3 (1.7%) 2 (3.4%) 0 1 (1.7%)
aMost common TEAEs in this table were those reported by ≥5% in any treatment group.
TEAEs = treatment-emergent adverse events.
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MWT trials at the 150 and 300 mg doses, effects that were
maintained over a 9-hour duration following dosing at the
12-week time point. This effect across the day may be lon-
ger in duration than what was observed in prior studies of
the wake-promoting agents armodafinil and modafinil in
patients with narcolepsy, where the effect appeared to
diminish during the 4th and 5th time trials later in the
day.27,28 However, definitive conclusions cannot be drawn
in the absence of comparative trials.
Differences from placebo for changes on the MWT in
the current study were 7.7 and 10.1 minutes for solriamfe-
tol 150 and 300 mg, respectively. These values are substan-
tially larger than what has been reported for modafinil, a
dopamine reuptake inhibitor that is currently one of the
most widely prescribed drugs for the treatment of ES in nar-
colepsy. Differences from placebo of 2.81 minutes (95%
CI = 2.10–3.53) and 2.82 minutes (95% CI = 2.40–3.24)
were reported in a meta-analysis of modafinil parallel-group
studies in narcolepsy and all modafinil narcolepsy studies
(ie, parallel-group and crossover combined), respectively,29
and the effects of modafinil were shown to be similar (ie,
noninferior) to pitolisant.30 Although the current clinical
trial utilized a 40-minute MWT, whereas other reports used
20- and 40-minute measurements,31–37 the apparently larger
effects of solriamfetol in this study may be related to its activ-
ity as a dual dopamine/norepinephrine reuptake inhibitor that
lacks the serotonergic effects or norepinephrine-releasing
effects of other drugs.38 The differences in ESS between sol-
riamfetol and placebo were −4.7 for 300 mg and −3.8 for
150 mg, whereas a difference of −2.73 (95% CI = −3.39 to
−2.00) was reported for modafinil in the meta-analysis.29
However, in the absence of head-to-head studies of solriamfe-
tol and modafinil/armodafinil, outcomes from this study can-
not be directly compared with results obtained with other
agents.
The increased wakefulness and reduced ES observed
with solriamfetol 150 and 300 mg paralleled global
improvements assessed from both the patients’ and clini-
cians’ perspectives.
The overall safety and tolerability in this study were
consistent with other studies of solriamfetol,17,18 with the
most common adverse events being headache, nausea,
decreased appetite, nasopharyngitis, dry mouth, and anxi-
ety; no serious adverse events were reported. Additionally,
small increases in mean blood pressure and heart rate were
observed, as previously reported with other wake-promoting
agents and psychostimulants.39
Conclusions with regard to the effect of solriamfetol
on cataplexy are limited by this study not being designed to
rigorously evaluate effects on cataplexy. The frequency of
type 2 narcolepsy (ie, without cataplexy) in approximately
50% of the study population was also somewhat higher than
TABLE 4. Change from Baseline to Last Assessment in Vital Signs (Patients with Nonmissing Values)
Vital Sign Placebo, n = 59 Solriamfetol
75 mg, n = 59 150 mg, n = 59 300 mg, n = 59 All Doses, n = 177
Patients with clinical laboratory
assessment data at week 12, na
50 48 49 43 140
Heart rate, beats/min 0.5  6.7 0.6  6.6 2.5  4.7 4.3  7.6 2.4  6.5
Blood pressure, mmHg
Systolic 0.6  8.1 0.3  6.8 1.2  7.4 2.0  7.4 1.2  7.2
Diastolic −0.6  5.2 1.0  4.4 1.4  4.9 2.1  5.0 1.5  4.8
Ambulatory blood pressure
monitoring in safety population
at week 8, nb
50 46 46 41 133
Heart rate, beats/min −0.6  7.0 1.0  8.0 0.7  7.1 5.3  7.6 2.2  7.8
Blood pressure, mmHg
Systolic −0.3  9.3 1.8  6.5 −0.5  5.5 2.4  6.0 1.2  6.1
Diastolic −0.1  7.2 1.4  5.1 0.4  4.5 3.0  5.0 1.6  4.9
Values are mean  standard deviation.
aVital signs averaged across predose to 9 hours postdose.
bVital signs matched by time point at baseline and week 8.
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reported in the narcolepsy literature.10 Whether the
observed effects on efficacy in this study can be maintained
without safety and tolerability concerns during long-term
treatment has been conducted, and results are currently
under review.
In conclusion, once-daily oral dosing of solriamfetol
150 and 300 mg resulted in major improvements in wake-
fulness and reductions in ES associated with narcolepsy
together with patient- and clinician-reported global
improvements. The safety profile was consistent with other
clinical studies of solriamfetol in narcolepsy. These results
demonstrate that solriamfetol represents an important
potential future therapeutic option for the treatment of
impaired wakefulness and ES in individuals with narcolepsy.
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